Search Results - "Kwak, Jae Yong"

Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE) by Do, Young Rok, Kwak, Jae‐Yong, Kim, Jeong A., Kim, Hyeoung Joon, Chung, Joo Seop, Shin, Ho‐Jin, Kim, Sung‐Hyun, Bunworasate, Udomsak, Choi, Chul Won, Zang, Dae Young, Oh, Suk Joong, Jootar, Saengsuree, Reksodiputro, Ary Harryanto, Lee, Won Sik, Mun, Yeung‐Chul, Kong, Jee Hyun, Caguioa, Priscilla B., Kim, Hawk, Park, Jinny, Kim, Dong‐Wook

“…Summary In the phase 3 study RERISE, patients with newly diagnosed chronic myeloid leukaemia in chronic phase demonstrated significantly faster and higher…”
Get full text

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study by Lee, Sung-Eun, Choi, Soo Young, Song, Hye-Young, Kim, Soo-Hyun, Choi, Mi-Yeon, Park, Joon Seong, Kim, Hyeoung-Joon, Kim, Sung-Hyun, Zang, Dae Young, Oh, Sukjoong, Kim, Hawk, Do, Young Rok, Kwak, Jae-Yong, Kim, Jeong-A, Kim, Dae-Young, Mun, Yeung-Chul, Lee, Won Sik, Chang, Myung Hee, Park, Jinny, Kwon, Ji Hyun, Kim, Dong-Wook

“…The aim of the Korean Imatinib Discontinuation Study was to identify predictors for safe and successful imatinib discontinuation. A total of 90 patients with a…”
Get full text

Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia by Kwak, Jae-Yong, Kim, Sung-Hyun, Oh, Suk Joong, Zang, Dae Young, Kim, Hawk, Kim, Jeong-A, Do, Young Rok, Kim, Hyeoung Joon, Park, Joon Seong, Choi, Chul Won, Lee, Won Sik, Mun, Yeung-Chul, Kong, Jee Hyun, Chung, Joo Seop, Shin, Ho-Jin, Kim, Dae-Young, Park, Jinny, Jung, Chul Won, Bunworasate, Udomsak, Comia, Narcisa Sonia, Jootar, Saengsuree, Reksodiputro, Arry Harryanto, Caguioa, Priscilla B, Lee, Sung-Eun, Kim, Dong-Wook

“…Radotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) approved in Korea for chronic phase chronic myeloid leukemia (CML-CP) in patients…”
Get full text

Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial by Park, Changhee, Lee, Ho Sup, Kang, Ka-Won, Lee, Won-Sik, Do, Young Rok, Kwak, Jae-Yong, Shin, Ho-Jin, Kim, Sung-Yong, Yi, Jun Ho, Lim, Sung-Nam, Lee, Jeong-Ok, Yang, Deok-Hwan, Jang, Hun, Choi, Byoungsan, Lim, Jiwoo, Sun, Choong Hyun, Byun, Ja Min, Yoon, Sung-Soo, Koh, Youngil

“…Potential synergism between Bruton’s tyrosine kinase (BTK) inhibitor and lenalidomide in treating aggressive B-cell lymphoma has been suggested. Here, the…”
Get full text

Fractalkine induces angiogenic potential in CX3CR1‐expressing monocytes by Park, Youngrok, Lee, Joon, Kwak, Jae‐Yong, Noh, Kyoungmi, Yim, Eunjung, Kim, Hyun‐Kyung, Kim, Young June, Broxmeyer, Hal E., Kim, Jeong‐A.

“…We report the unique role of CX3CL1 (or fractalkine) on CD11b+ myelomonocytic cells expressing CX3CR1, the only known receptor for CX3CL1, in promoting blood…”
Get full text

First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial by Yhim, Ho-Young, Yoon, Dok Hyun, Kim, Seok Jin, Yang, Deok-Hwan, Eom, Hyeon-Seok, Kim, Kyoung Ha, Park, Yong, Kim, Jin Seok, Kim, Hyo Jung, Suh, Cheolwon, Kim, Won Seog, Kwak, Jae-Yong

“…There are limited data from prospective controlled trials regarding optimal treatment strategies in patients with primary breast diffuse large B-cell lymphoma…”
Get full text

Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy by Yhim, Ho-Young, Kim, Jin Seok, Kang, Hye Jin, Kim, Seok Jin, Kim, Won Seog, Choi, Chul Won, Eom, Hyeon Seok, Kim, Jeong-A., Lee, Jae Hoon, Won, Jong Ho, Shim, Hyeok, Huh, Jooryung, Lee, Dae-Ho, Suh, Cheolwon, Kwak, Jae-Yong

“…Primary breast diffuse large B‐cell lymphoma (DLBCL) is an extremely rare presentation of non‐Hodgkin's lymphoma that has been associated with poorer clinical…”
Get full text

Early risk stratification for diffuse large B-cell lymphoma integrating interim Deauville score and International Prognostic Index by Yim, Sung Kyun, Yhim, Ho-Young, Han, Yeon-Hee, Jeon, So-Yeon, Lee, Na-Ri, Song, Eun-Kee, Jeong, Hwan-Jeong, Kim, Hee Sun, Kwak, Jae-Yong

“…The aim of this study was to evaluate the prognostic relevance of early risk stratification in diffuse large B-cell lymphoma (DLBCL) using interim Deauville…”
Get full text

Primary Natural Killer/T-Cell Lymphoma of the Ribs by Kim, Kyoung Min, Jang, Kyu Yun, Kwak, Jae-Yong, Ahn, Ae Ri

Get full text

Risk stratification for early mortality in newly diagnosed acute promyelocytic leukemia: a multicenter, non-selected, retrospective cohort study by Kim, Suhyeon, Jung, Jiye, Ahn, Seo-Yeon, Kim, Mihee, Jeon, So Yeon, Lee, Chang-Hoon, Kim, Dae Sik, Lee, Se Ryeon, Sung, Hwa Jung, Choi, Chul Won, Kim, Byung-Soo, Kim, Hyeoung-Joon, Kwak, Jae-Yong, Park, Yong, Ahn, Jae-Sook, Yhim, Ho-Young

“…Despite the current effective treatments for acute promyelocytic leukemia (APL), early mortality (EM), defined as death within 30 days of presentation, is a…”
Get full text

Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia by Yoon, Sang Eun, Song, Yuqin, Kim, Seok Jin, Yoon, Dok Hyun, Chen, Tsai-Yun, Koh, Youngil, Kang, Ka Won, Lee, Ho Sup, Tay, Kevin Kuang Wei, Lim, Soon Thye, Poon, Michele, Irawan, Cosphiadi, Zhao, Weili, Do, Young Rok, Lee, Mark Hong, Ng, Soo Chin, Lee, Won-Sik, Guo, Ye, Zhang, Huilai, Kang, Hye Jin, Yun, Hwan Jung, Kim, Hyo Jung, Lung, Daryl Tan Chen, Kwak, Jae-Yong, Han, Jae Joon, Mun, Yeung-Chul, Oh, Sung Yong, Shim, Hyeok, Kwon, Jung Hye, Sohn, Byeong Seok, Park, Seong Kyu, Jo, Jae-Cheol, Ko, Young Hyeh, Jun, Zhu, Kim, Won Seog

“…Peripheral T-cell lymphomas (PTCLs) are uncommon and their frequency is regionally heterogeneous. Several studies have been conducted to evaluate the clinical…”
Get full text

Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study by Yhim, Ho-Young, Park, Yong, Kim, Jeong-A, Shin, Ho-Jin, Do, Young Rok, Moon, Joon Ho, Kim, Min Kyoung, Lee, Won Sik, Kim, Dae Sik, Lee, Myung-Won, Choi, Yoon Seok, Jeong, Seong Hyun, Kim, Kyoung Ha, Kim, Jinhang, Lee, Chang-Hoon, Song, Ga-Young, Yang, Deok-Hwan, Kwak, Jae-Yong

“…Optimal risk stratification based on simplified geriatric assessment to predict treatment-related toxicity and survival needs to be clarified in older patients…”
Get full text

Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL) by Kim, Seok Jin, Choi, Chul Won, Mun, Yeung-Chul, Oh, Sung Yong, Kang, Hye Jin, Lee, Soon Il, Won, Jong Ho, Kim, Min Kyoung, Kwon, Jung Hye, Kim, Jin Seok, Kwak, Jae-Yong, Kwon, Jung Mi, Hwang, In Gyu, Kim, Hyo Jung, Lee, Jae Hoon, Oh, Sukjoong, Park, Keon Woo, Suh, Cheolwon, Kim, Won Seog

“…Primary intestinal non-Hodgkin lymphoma (NHL) is a heterogeneous disease with regard to anatomic and histologic distribution. Thus, analyses focusing on…”
Get full text

A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score by Yhim, Ho-Young, Park, Yong, Han, Yeon-Hee, Kim, Sungeun, Kang, Sae-Ryung, Moon, Joon-Ho, Jeong, Ju Hye, Shin, Ho-Jin, Kim, Keunyoung, Choi, Yoon Seok, Kim, Kunho, Kim, Min Kyoung, Kong, Eunjung, Kim, Dae Sik, Eo, Jae Seon, Lee, Ji Hyun, Kang, Do-Young, Lee, Won Sik, Lee, Seok Mo, Do, Young Rok, Ham, Jun Soo, Kim, Seok Jin, Kim, Won Seog, Choi, Joon Young, Yang, Deok-Hwan, Kwak, Jae-Yong

“…Purpose The aim of this study was to establish a risk-stratification model integrating posttreatment metabolic response using the Deauville score and the…”
Get full text

A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study by Kim, Seok Jin, Do, Young Rok, Lee, Ho-Sup, Lee, Won-Sik, Kong, Jee Hyun, Kwak, Jae-Yong, Eom, Hyeon-Seok, Moon, Joon Ho, Yi, Jun Ho, Lee, Jeong-Ok, Jo, Jae-Cheol, Yang, Deok-Hwan

“…Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. In Korea, BV has been approved for the treatment of relapsed or…”
Get full text

Prognostic significance of FDG-PET/CT in determining upfront autologous stem cell transplantation for the treatment of peripheral T cell lymphomas by Ahn, Seo-Yeon, Jung, Seung-Yeon, Jung, Sung-Hoon, Ahn, Jae-Sook, Lee, Je-Jung, Kim, Hyeoung-Joon, Kang, Sae-Ryung, Han, Yeon-Hee, Kwak, Jae-Yong, Yhim, Ho-Young, Yang, Deok-Hwan

“…This observational study aimed to evaluate the prognostic significance of interim and final 18 F-fluorodeoxyglucose positron emission tomography-computed…”
Get full text

Real‐world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis by Yi, Jun Ho, Kim, Seok Jin, Yoon, Dok Hyun, Suh, Cheolwon, Chang, Myung Hee, Yang, Deok Hwan, Jo, Jae‐Cheol, Hyun, Shin Young, Eom, Hyeon‐Seok, Lee, Jeong‐Ok, Kwon, Ji Hyun, Han, Sang Hoon, Lee, Seung‐Shin, Kwak, Jae‐Yong, Kim, Se Hyung, Kim, Dae Sik, Lee, Ji Hyun, Oh, Sung Yong, Ryoo, Hun Mo, Kim, Hyo Jung, Kim, Won Seog

“…Abbreviations AE adverse event ASCT autologous stem cell transplantation CI confidence interval CR complete response MCL mantle cell lymphoma ORR overall…”
Get full text

Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts by Yi, Jun Ho, Jeong, Seong Hyun, Kim, Seok Jin, Yoon, Dok Hyun, Kang, Hye Jin, Koh, Youngil, Kim, Jin Seok, Lee, Won-Sik, Yang, Deok-Hwan, Do, Young Rok, Kim, Min Kyoung, Yoo, Kwai Han, Choi, Yoon Seok, Yun, Whan Jung, Park, Yong, Jo, Jae-Cheol, Eom, Hyeon-Seok, Kwak, Jae-Yong, Shin, Ho-Jin, Park, Byeong Bae, Yi, Seong Yoon, Kwon, Ji-Hyun, Oh, Sung Yong, Kim, Hyo Jung, Sohn, Byeong Seok, Won, Jong Ho, Hong, Dae-Sik, Lee, Ho-Sup, Lee, Gyeong-Won, Suh, Cheolwon, Kim, Won Seog

“…Diffuse large B-cell lymphoma (DLBCL) is the most common hematologic malignancy worldwide. Although substantial improvement has been achieved by the frontline…”
Get full text

Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia by Lee, Yong-Pyo, Yoon, Sang Eun, Song, Yuqin, Kim, Seok Jin, Yoon, Dok Hyun, Chen, Tsai-Yun, Koh, Young Il, Kang, Ka Won, Lee, Ho sup, Wei, Kevin Tay Kuang, Lim, Soon Thye, Poon, Michelle, Irawan, Cosphiadi, Zhao, Weili, Do, Young Rok, Lee, Mark Hong, Ng, Soo Chin, Lee, Won-Sik, Guo, Ye, Zhang, Huilai, Kang, Hye-Jin, Yun, Hwan Jung, Kim, Hyo Jung, Lung, Daryl Tan Chen, Kwak, Jae-Yong, Han, Jae Joon, Mun, Yeung-Chul, Oh, Sung Yong, Shim, Hyeok, Kwon, Jung Hye, Sohn, Byeong Seok, Park, Seong Kyu, Jo, Jae Cheol, Ko, Young Hyeh, Jun, Zhu, Kim, Won Seog

“…Cutaneous T-cell lymphomas (CTCLs) are a group of T-cell lymphomas with low incidence. Due to their indolent characteristics, treatment strategies have not yet…”
Get full text

The prognostic significance of tumor human papillomavirus status for patients with anal squamous cell carcinoma treated with combined chemoradiotherapy by Yhim, Ho‐Young, Lee, Na‐Ri, Song, Eun‐Kee, Kwak, Jae‐Yong, Lee, Soo Teik, Kim, Jong Hun, Kim, Jung‐Soo, Park, Ho Sung, Chung, Ik‐Joo, Shim, Hyun‐Jeong, Hwang, Jun‐Eul, Kim, Hyeong Rok, Nam, Taek‐Keun, Park, Moo‐Rim, Shim, Hyeok, Park, Hyo Sook, Kim, Hee Sun, Yim, Chang‐Yeol

“…The prognostic relevance of tumor human papillomavirus (HPV) status in anal squamous cell carcinoma (SCC) had not been previously investigated, although its…”
Get full text